litlas
Log inCreate account

Roy S. Herbst

Active 1984–2025

258
Papers
84,011
Citations
134
h-index
248
i10-index

Citations

Citations per year for Roy S. Herbst1951: 1 citations1971: 1 citations1984: 1 citations1985: 3 citations1986: 7 citations1987: 6 citations1988: 15 citations1989: 15 citations1990: 23 citations1991: 11 citations1992: 6 citations1993: 6 citations1994: 1 citations1995: 4 citations1997: 3 citations1998: 3 citations1999: 3 citations2000: 7 citations2001: 26 citations2002: 70 citations2003: 135 citations2004: 230 citations2005: 490 citations2006: 517 citations2007: 496 citations2008: 460 citations2009: 584 citations2010: 466 citations2011: 470 citations2012: 386 citations2013: 504 citations2014: 396 citations2015: 621 citations2016: 873 citations2017: 871 citations2018: 923 citations2019: 2,672 citations2020: 3,418 citations2021: 3,972 citations2022: 3,220 citations2023: 2,401 citations2024: 3,282 citations2025: 1,538 citations2026: 32 citations1952–1970: no citations, so these years are not shown1972–1983: no citations, so these years are not shown1996: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 8,990 citing papers, 25.2% of this breakdownChina: 6,498 citing papers, 18.2% of this breakdownItaly: 1,678 citing papers, 4.7% of this breakdownUnited Kingdom: 1,613 citing papers, 4.5% of this breakdownJapan: 1,527 citing papers, 4.3% of this breakdownGermany: 1,440 citing papers, 4% of this breakdownFrance: 1,396 citing papers, 3.9% of this breakdownSpain: 1,132 citing papers, 3.2% of this breakdownCanada: 1,072 citing papers, 3% of this breakdownSouth Korea: 888 citing papers, 2.5% of this breakdownNetherlands: 831 citing papers, 2.3% of this breakdownAustralia: 777 citing papers, 2.2% of this breakdown
0%25.2%Other 22%

Institutions

Fields

  • Medicine66.1%
  • Biochemistry, Genetics and Molecular Biology22.5%
  • Immunology and Microbiology5.8%
  • Engineering1.2%
  • Computer Science0.8%
  • Neuroscience0.7%
  • Other2.9%

Topics

  • Cancer Immunotherapy and Biomarkers11.6%
  • Lung Cancer Treatments and Mutations7.7%
  • Lung Cancer Research Studies3.8%
  • Immunotherapy and Immune Responses3.5%
  • Lung Cancer Diagnosis and Treatment3.3%
  • Cancer Genomics and Diagnostics2.7%
  • Other67.4%

Coauthors

All papers

Open in search
  1. The biology and management of non-small cell lung cancer

    Authors: Roy S. Herbst, Daniel Morgensztern, Chris Boshoff - Nature 2018 cited by 5,055

  2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

    Authors: Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon - The Lancet 2015 cited by 6,537

  3. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Authors: Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Gregg Fine, Omid Hamid, Michael S. Gordon, Jeffery A. Sosman, David F. McDermott, John D. Powderly, Scott Gettinger, Holbrook E. Kohrt, Leora Horn, Donald P. Lawrence, Sandra Rost, Maya K. Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, Daniel S. Chen, F. Stephen Hodi - Nature 2014 cited by 5,302

  4. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

    Authors: Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Wei Zou, Alan Sandler, Ida Enquist, Kimberly M. Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Mark L. McCleland, Simonetta Mocci, Jacek Jassem, David R. Spigel - New England Journal of Medicine 2020 cited by 1,691

  5. Toward personalized treatment approaches for non-small-cell lung cancer

    Authors: Meina Wang, Roy S. Herbst, Chris Boshoff - Nature Medicine 2021 cited by 1,140

  6. Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

    Authors: Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst - New England Journal of Medicine 2020 cited by 1,756

  7. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

    Authors: Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohé, Jie Wang, Jonathan W. Goldman, Shun Lü, Wu‐Chou Su, Filippo de Marinis, Frances A. Shepherd, Ki Hyeong Lee, Nhieu Thi Le, Arunee Dechaphunkul, Dariusz M. Kowalski, Lynne Poole, Ana Bolanos, Yuri Rukazenkov, Yi‐Long Wu - New England Journal of Medicine 2023 cited by 612

  8. Longitudinal analyses reveal immunological misfiring in severe COVID-19

    Authors: Carolina Lucas, Patrick Wong, Jon Klein, Tiago B. R. Castro, Julio Silva, Maria E. Sundaram, Mallory K. Ellingson, Tianyang Mao, Ji Eun Oh, Benjamin Israelow, Takehiro Takahashi, Maria Tokuyama, Peiwen Lu, Arvind Venkataraman, Annsea Park, Subhasis Mohanty, Haowei Wang, Anne L. Wyllie, Chantal B. F. Vogels, Rebecca Earnest, Sarah Lapidus, Isabel M. Ott, Adam J. Moore, M. Catherine Muenker, John Fournier, Melissa Campbell, Camila D. Odio, Arnau Casanovas‐Massana, Yale IMPACT Team, Abeer Obaid, Alice Lu-Culligan, Allison Nelson, Anderson F. Brito, Ángela Núñez, Anjelica Martin, Annie Watkins, Bertie Geng, Chaney C. Kalinich, Christina A. Harden, Codruta Todeasa, Cole Jensen, Daniel Kim, David McDonald, Denise Shepard, Edward Courchaine, Elizabeth B. White, Eric Song, Erin Silva, Eriko Kudo, Giuseppe DeIuliis, Harold Rahming, Hong‐Jai Park, Irene Matos, Jessica Nouws, Jordan Valdez, Joseph R. Fauver, Joseph K. Lim, Kadi-Ann Rose, Kelly Anastasio, Kristina Brower, Laura Glick, Lokesh Sharma, Lorenzo R. Sewanan, Lynda Knaggs, Maksym Minasyan, Maria Batsu, Mary E. Petrone, Maxine Kuang, Maura Nakahata, Melissa Campbell, Melissa Linehan, Michael H. Askenase, Michael Simonov, Mikhail Smolgovsky, Nicole Sonnert, Nida Naushad, Pavithra Vijayakumar, Rick Martinello, Rupak Datta, Ryan Handoko, Santos Bermejo, Sarah Prophet, Sean Bickerton, Sofia Velazquez, Tara Alpert, Tyler Rice, William Khoury-Hanold, Xiaohua Peng, Yexin Yang, Yiyun Cao, Yvette Strong, Roy S. Herbst, Albert C. Shaw, Ruslan Medzhitov, Wade L. Schulz, Nathan D. Grubaugh, Charles S. Dela Cruz, Shelli Farhadian, Albert I. Ko, Saad B. Omer and 1 more - Nature 2020 cited by 2,319

  9. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

    Authors: Scott Gettinger, Jungmin Choi, Katherine Hastings, Anna Truini, Ila Datar, Ryan Sowell, Anna Wurtz, Weilai Dong, Guoping Cai, Mary Ann Melnick, Victor Y. Du, Joseph Schlessinger, Sarah B. Goldberg, Anne C. Chiang, Miguel F. Sanmamed, Ignacio Melero, Jackeline Agorreta, Luis M. Montuenga, Richard P. Lifton, Soldano Ferrone, Paula Kavathas, David L. Rimm, Susan M. Kaech, Kurt A. Schalper, Roy S. Herbst, Katerina Politi - Cancer Discovery 2017 cited by 755

  10. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities

    Authors: Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, Lieping Chen - Nature Reviews Drug Discovery 2022 cited by 347

  11. Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

    Authors: Ferdinandos Skoulidis, Lauren A. Byers, Lixia Diao, Vassiliki A. Papadimitrakopoulou, Pan Tong, Julie Izzo, Carmen Behrens, Humam Kadara, Edwin R. Parra, Jaime Rodriguez Canales, Jianjun Zhang, Uma Giri, Jayanthi Gudikote, María Angélica Cortez, Chao Yang, You-Hong Fan, Michael Peyton, Luc Girard, Kevin R. Coombes, Carlo Toniatti, Timothy P. Heffernan, Murim Choi, Garrett M. Frampton, Vincent A. Miller, John N. Weinstein, Roy S. Herbst, Kwok‐Kin Wong, Jianhua Zhang, Padmanee Sharma, Gordon B. Mills, Waun Ki Hong, John D. Minna, James P. Allison, P. Andrew Futreal, Jing Wang, Ignacio I. Wistuba, John V. Heymach - Cancer Discovery 2015 cited by 916

  12. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

    Authors: Jun Wang, Jingwei Sun, Linda N. Liu, Dallas B. Flies, Xinxin Nie, Maria Toki, Jianping Zhang, Chang Song, Melissa Zarr, Xu Zhou, Xue Han, Kristina A. Archer, Thomas O’Neill, Roy S. Herbst, Agedi Boto, Miguel F. Sanmamed, Solomon Langermann, David L. Rimm, Lieping Chen - Nature Medicine 2019 cited by 697

  13. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer

    Authors: Roy S. Herbst, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Quincy Chu, Isabelle Monnet, Alfredo Sanchez-Hernandez, Shaker Dakhil, D. Ross Camidge, Leanne Winzer, Yee Soo-Hoo, Zachary A. Cooper, Rakesh Kumar, John Bothos, Charu Aggarwal, Alex Martinez-Marti - Journal of Clinical Oncology 2022 cited by 287

  14. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

    Authors: Roy S. Herbst, Yi‐Long Wu, Thomas John, Christian Grohé, Margarita Majem, Jie Wang, Terufumi Kato, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Chong‐Jen Yu, Hữu Vĩnh Vũ, Shun Lü, Kye Young Lee, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Damien Urban, Xiangning Huang, Ana Bolanos, Marta Stachowiak, Masahiro Tsuboi - Journal of Clinical Oncology 2023 cited by 389

  15. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

    Authors: Sarah B. Goldberg, Kurt A. Schalper, Scott Gettinger, Amit Mahajan, Roy S. Herbst, Anne C. Chiang, Rogério Lilenbaum, Frederick H. Wilson, Sacit Bulent Omay, James B. Yu, Lucia B. Jilaveanu, Thuy Tran, Kira F. Pavlik, Elin Rowen, Heather Gerrish, Annette Komlo, Richa Gupta, Hailey Wyatt, Matthew Ribeiro, Yuval Kluger, Geyu Zhou, Wei Wei, Veronica Chiang, Harriet M. Kluger - The Lancet Oncology 2020 cited by 538

  16. An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

    Authors: Lauren A. Byers, Lixia Diao, Jing Wang, Pierre Saintigny, Luc Girard, Michael Peyton, Li Shen, You-Hong Fan, Uma Giri, Praveen K. Tumula, Monique B. Nilsson, Jayanthi Gudikote, Hai T. Tran, Robert J. Cardnell, David J. Bearss, Steven L. Warner, Jason M. Foulks, Steven B. Kanner, Varsha Gandhi, Nancy Krett, Steven T. Rosen, Edward S. Kim, Roy S. Herbst, George R. Blumenschein, J. Jack Lee, Scott M. Lippman, K. Kian Ang, Gordon B. Mills, Waun Ki Hong, John N. Weinstein, Ignacio I. Wistuba, Kevin R. Coombes, John D. Minna, John V. Heymach - Clinical Cancer Research 2012 cited by 1,121

  17. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells

    Authors: Matthew B. Dong, Guangchuan Wang, Ryan D. Chow, Lupeng Ye, Lvyun Zhu, Xiaoyun Dai, Jonathan J. Park, Hyunu R. Kim, Youssef Errami, Christopher D. Guzman, Xiaoyu Zhou, Krista Y. Chen, Paul Renauer, Yaying Du, Johanna Shen, Stanley Z. Lam, J. Zhou, Donald R. Lannin, Roy S. Herbst, Sidi Chen - Cell 2019 cited by 328

  18. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

    Authors: Arvind Ravi, Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T. Griffin, Natalie I. Vokes, Mustafa Sakhi, Vashine Kamesan, Hira Rizvi, Biagio Ricciuti, Patrick M. Forde, Valsamo Anagnostou, Jonathan W. Riess, Don L. Gibbons, Nathan A. Pennell, Vamsidhar Velcheti, Subba R. Digumarthy, Mari Mino–Kenudson, Andrea Califano, John V. Heymach, Roy S. Herbst, Julie R. Brahmer, Kurt A. Schalper, Victor E. Velculescu, Brian S. Henick, Naiyer A. Rizvi, Pasi A. Jänne, Mark M. Awad, Andrew Chow, Benjamin D. Greenbaum, Marta Łuksza, Alice T. Shaw, Jedd D. Wolchok, Nir Hacohen, Gad Getz, Justin F. Gainor - Nature Genetics 2023 cited by 186

  19. Lung Cancer

    Authors: Roy S. Herbst, John V. Heymach, Scott M. Lippman - New England Journal of Medicine 2008 cited by 2,390

  20. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes

    Authors: Deborah B. Doroshow, Miguel F. Sanmamed, Katherine Hastings, Katerina Politi, David L. Rimm, Lieping Chen, Ignacio Melero, Kurt A. Schalper, Roy S. Herbst - Clinical Cancer Research 2019 cited by 718

  21. Review of epidermal growth factor receptor biology

    Authors: Roy S. Herbst - International Journal of Radiation Oncology*Biology*Physics 2004 cited by 1,404

  22. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

    Authors: Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Katherine Minichiello, Liza C. Villaruz, Bryan A. Faller, Tareq Al Baghdadi, Susan J. Hines, Leah Everhart, Louise Highleyman, Vassiliki A. Papadimitrakopoulou, Joel W. Neal, Saiama N. Waqar, Jyoti D. Patel, Jhanelle E. Gray, David R. Gandara, Karen Kelly, Roy S. Herbst - Journal of Clinical Oncology 2022 cited by 240

  23. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

    Authors: Yuting Liu, Jon Zugazagoitia, Fahad Shabbir Ahmed, Brian S. Henick, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, David L. Rimm - Clinical Cancer Research 2019 cited by 337

  24. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

    Authors: Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, Radj Gervais, José Luis Perez‐Gracia, Ji‐Youn Han, Margarita Majem, Martin Förster, I. Monnet, Silvia Novello, Matthew A. Gubens, Michael Boyer, Wu‐Chou Su, Ayman Samkari, Erin Jensen, Julie Kobie, Bilal Piperdi, Paul Baas - Journal of Thoracic Oncology 2021 cited by 312